Kephera Diagnostics
Kephera Diagnostics is an innovative company focused on developing diagnostics for emerging and neglected infectious diseases. Their mission is to promote more effective and affordable treatment through faster, point-of-care diagnosis, collaborating with global research institutions to develop accessible diagnostic products. The company is actively engaged in developing and launching a variety of diagnostic tests, including CLIA-certified laboratory tests and point-of-care assays, for diseases such as COVID-19, Chagas disease, neurocysticercosis, liver fluke infection, and parasitic diseases. Kephera also collaborates with public health agencies like the CDC and NIH, and is involved in research and development of immunoassays, molecular tools, and rapid testing platforms to address global health challenges.
Industries
Nr. of Employees
small (1-50)
Kephera Diagnostics
1 Grant Street, Suite 300, Framingham, MA 01702
Products
Chagas serodiagnostic algorithm (laboratory service)
Laboratory serology service using parallel testing on two serological assays with an immunoblot tiebreaker to provide definitive serodiagnosis for Trypanosoma cruzi infection.
Point-of-care assay development programs (parasitic and viral targets)
R&D programs to develop rapid POC assays (antigen and antibody) and corresponding laboratory tests for multiple pathogens, with an emphasis on formats suitable for field deployment.
Laboratory ELISA and multiplex serology services
Provision and development of ELISA-based and multiplex immunoassays for detection of pathogen-specific antibodies for clinical, surveillance and research applications.
Quantitative COVID-19 antibody test (laboratory service)
A laboratory service that measures IgG antibody levels to the SARS-CoV-2 spike protein on an international standard, intended to quantify vaccine- or infection-elicited antibody responses.
Chagas serodiagnostic algorithm (laboratory service)
Laboratory serology service using parallel testing on two serological assays with an immunoblot tiebreaker to provide definitive serodiagnosis for Trypanosoma cruzi infection.
Point-of-care assay development programs (parasitic and viral targets)
R&D programs to develop rapid POC assays (antigen and antibody) and corresponding laboratory tests for multiple pathogens, with an emphasis on formats suitable for field deployment.
Laboratory ELISA and multiplex serology services
Provision and development of ELISA-based and multiplex immunoassays for detection of pathogen-specific antibodies for clinical, surveillance and research applications.
Quantitative COVID-19 antibody test (laboratory service)
A laboratory service that measures IgG antibody levels to the SARS-CoV-2 spike protein on an international standard, intended to quantify vaccine- or infection-elicited antibody responses.
Services
High-complexity laboratory testing available to clinicians and institutions with sample submission, test ordering, defined pre-analytical procedures, and result reporting.
High-complexity laboratory testing available to clinicians and institutions with sample submission, test ordering, defined pre-analytical procedures, and result reporting.
Expertise Areas
- Point-of-care diagnostic platform development
- Microfluidic assay engineering
- Immunoassay and serology development
- Lateral flow and paper microfluidics
Key Technologies
- Microfluidic cassette point-of-care platform
- Lateral flow immunoassays
- Enzyme-linked immunosorbent assay (ELISA)
- Multiplex immunoassays
News & Updates
Kephera Diagnostics announced the launch of CLIA laboratory tests for Chagas disease, neurocysticercosis, and liver fluke infection, adding to its existing tests for Lyme disease. The tests include FDA-approved ELISA and multiplex serological tests, following CDC algorithms for diagnosis.
Kephera received a $1,989,300 grant from NIAID to develop a Zika virus antibody test.
Kephera Diagnostics announced the launch of CLIA laboratory tests for Chagas disease, neurocysticercosis, and liver fluke infection, adding to its existing tests for Lyme disease. The tests include FDA-approved ELISA and multiplex serological tests, following CDC algorithms for diagnosis.
Kephera received a $1,989,300 grant from NIAID to develop a Zika virus antibody test.